

## DECEMBER 2019

INOVIO coronavirus experts learn about a novel coronavirus (SARS-CoV-2) that caused an outbreak of respiratory disease in Wuhan, China, now referred to as COVID-19

## JANUARY 10/11, 2020

Chinese researchers share the genetic sequence of the novel coronavirus on 1/10

INOVIO designs DNA vaccine INO-4800 in three hours after receiving the genetic sequence late in the evening on 1/10 using its proprietary DNA medicines platform technology

INO-4800 was designed just after midnight on 1/11 to precisely match the DNA sequence of the virus

## JANUARY 10 - JANUARY 23, 2020

INOVIO coronavirus experts race to manufacture INO-4800 and begin preclinical testing and clinical trial design

## JANUARY 23, 2020

INOVIO receives a grant of up to \$9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund ongoing preclinical and initial clinical development of INO-4800

CEPI

## MARCH 2020

Ongoing preclinical studies, including challenge studies; human clinical trial designs finalized; 3,000 human trial doses prepared for clinical trials in the U.S., China, and South Korea; large-scale manufacturing plans developed

## MARCH 12, 2020

INOVIO announces \$5 million grant from the Bill & Melinda Gates Foundation to continue advancing the development of INO-4800, specifically to accelerate the testing and scale up of INOVIO's proprietary smart device CELLECTRA® 3PSP

BILL & MELINDA GATES foundation

## MARCH 26, 2020

INOVIO announces the Department of Defense (DoD) awarded Ology Bioservices an \$11.9 million contract to work with INOVIO on DNA technology transfer to rapidly manufacture INO-4800 for the DoD for upcoming clinical trials



## APRIL 6 - 23, 2020

INOVIO announces initiation of Phase 1 human clinical trial in the U.S. following authorization by the U.S. Food and Drug Administration of its Investigational New Drug (IND) application

U.S. study fully enrolls 40 healthy volunteers; study sites are the University of Pennsylvania and a clinic in Kansas City, MO

Clinical trials and preclinical challenge studies continue

## MAY 20, 2020


Preclinical data (in mice and guinea pigs) published in peer-reviewed journal Nature Communications

nature COMMUNICATIONS

## JUNE/JULY 2020

Phase 1 trial expanded with 80 additional participants (older adults, low-dose arm)

INOVIO receives \$71 million from DoD to scale up manufacture of CELLECTRA 3PSP and procurement of CELLECTRA® 2000 (6/23)



INOVIO announces positive interim Phase 1 data for INO-4800 (6/30); durable antibody and T cell responses in NHPs challenged with SARS-CoV-2 (7/30)

Phase 1/2 trials begin in South Korea, China

## SEPTEMBER 2020

Phase 2/3 trials expected to begin\*

## ONGOING

INO-4800 COVID-19 DNA vaccine production and scale up underway\*

\*Pending appropriate regulatory guidance and external funding

